胃潰瘍預防的一般實踐變化:一項以全國登錄為基礎的研究
Peter Fentz Haastrup1, Jane Møller Hansen2, Jens Søndergaard1
1Research Unit of General Practice, Department of Public Health, University of Southern Denmark, Odense, Denmark.
Scandinavian journal of primary health care
|August 30, 2024
概括
质子抑制剂 (PPI) 在胃出血预防中处方不足在丹麦的一般诊所中很常见. 很少有实践特征影响了PPI的使用,强调了需要更好的风险识别方法.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 一般实践 一般实践
背景情况:
- 胃潰瘍出血的發生率可以用預防性陽子抑制劑 (PPI) 減少.
- 然而,PPI的使用在风险患者之间有所不同,这表明潜在的处方不足.
- 在一般实践环境中这种变化的程度尚不清楚.
研究的目的:
- 分析丹麦一般诊所中接受PPI预防的高风险患者的比例.
- 调查一般实践特征与用于预防出血的PPI处方之间的关联.
主要方法:
- 全国范围的基于注册的横截面研究.
- 在丹麦的全科医院内分析患有出血风险的患者.
- 后勤回归用于检查与PPI治疗的实践特征关联.
主要成果:
- 在大多数一般实践中,不到40%的风险患者被个人保护剂所覆盖.
- 观察到PPI覆盖范围的地理差异,首都以外的比率更高.
- 较老,女性主导和伙伴关系实践显示,与年轻或男性主导实践相比,PPI覆盖率更高.
结论:
- 在各种一般实践类型中,预防的处方不足显著.
- 很少有实践特征与PPI处方模式密切相关.
- 需要新的方法来帮助全科医生识别患有并发症风险的患者.
相关概念视频
Peptic Ulcer Disease IV: Management
78
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
78
Peptic Ulcer Disease I: Introduction
148
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
148
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
358
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
358
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
361
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
361
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
375
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
375
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
335
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
335


